The mechanism we're betting on.
Rare autoimmune cartilage disorder. Cross-walks with the RA mechanism stack with cartilage-specific anti-inflammatory and proteostasis modifiers. Designed under rare-disease regulatory pathway. The full mechanism map — including compound list, dose escalation, pre-specified biomarker thresholds, and the cross-walk modifiers used when re-fitting blends from related indications — is part of the gated methodology pack.Gated
What the rest of the world is doing.
Numbers below are surfaced by Atlas Bio's ClinicalTrials.gov and PubMed RWE pipelines, run against the Relapsing Polychondritis indication. Counts are industry-wide trials registered on ClinicalTrials.gov, not Atlas Bio studies. Methodology →
- Self-expanding tracheobronchial stents in the management of major airway problems. · PMID 7932334 · Journal of the Royal College of Surgeons of Edinburgh · 1994
Locked before readout.
Predictions for this study are SHA-256 locked before any readout. Pre-registration covers target engagement, primary endpoint, secondary endpoints, and the falsification criterion. The hash, prediction wording, and timestamp are available to verified clinicians and indication researchers on request.Gated
Same stack, every indication.
- M2 · Pre-Registration — SHA-256 locking before readout.
- M1 · IBC Reasoning — 19-agent audit (11 core + 8 reasoning nodes).
- M3 · Cross-Trial Validation — mechanism-anchored bridging across indications.
- M4 · RWE Pipelines — ClinicalTrials.gov, PubMed, FDA, EDGAR feeds (the source of the numbers above).
Want the full Relapsing Polychondritis protocol?
The abstract above is open. Compound lists, dose escalations, SHA-256-locked prediction documents, agent-network reasoning chains, and trial design specifics are available to verified clinicians, indication researchers, and sponsors under MNDA. Contact management to begin the access request.
Contact management →